221 related articles for article (PubMed ID: 36257585)
1. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.
Wen J; Yang H; Liu MZ; Luo KJ; Liu H; Hu Y; Zhang X; Lai RC; Lin T; Wang HY; Fu JH
Ann Oncol; 2014 Sep; 25(9):1769-1774. PubMed ID: 24907633
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
6. Identification of m
Ma Y; Sun Y; Zhao X; Li J; Fu X; Gong T; Zhang X
Sci Rep; 2023 Sep; 13(1):14499. PubMed ID: 37666951
[TBL] [Abstract][Full Text] [Related]
7. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
8. Identification of a nomogram based on long non-coding RNA to improve prognosis prediction of esophageal squamous cell carcinoma.
Li W; Liu J; Zhao H
Aging (Albany NY); 2020 Jan; 12(2):1512-1526. PubMed ID: 31978896
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Exosome-Related LncRNA Pairs as Predictors for Immune Microenvironment, Survival Outcome, and Microbiotain Landscape in Esophageal Squamous Cell Carcinoma.
Zhao F; Li Z; Dong Z; Wang Z; Guo P; Zhang D; Li S
Front Immunol; 2022; 13():918154. PubMed ID: 35880180
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
[TBL] [Abstract][Full Text] [Related]
11. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
12. A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy.
Zhang C; Zhang Z; Zhang G; Xue L; Yang H; Luo Y; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Zhang Z; Wang L; Che Y; Wang S; Wang F; Fang L; Zeng Q; Li J; Gao S; Xue Q; Sun N; He J
Clin Transl Med; 2020 Aug; 10(4):e156. PubMed ID: 32898328
[TBL] [Abstract][Full Text] [Related]
13. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Xue L; Zhang Z; Yang H; Luo Y; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Wang L; Che Y; Wang F; Wang S; Gao S; Xue Q; Zhang Y; He J
Signal Transduct Target Ther; 2020 Sep; 5(1):182. PubMed ID: 32883946
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
15. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
[TBL] [Abstract][Full Text] [Related]
16. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
Zhang Z; Wang J; Han W; Zhao L
BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
[TBL] [Abstract][Full Text] [Related]
17. Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma.
Yuan J; Weng Z; Tan Z; Luo K; Zhong J; Xie X; Qu C; Lin X; Yang H; Wen J; Fu J
Cancer Lett; 2023 Jan; 553():215959. PubMed ID: 36279981
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.
Shi X; Li Y; Pan S; Liu X; Ke Y; Guo W; Wang Y; Ruan Q; Zhang X; Ma H
Sci Rep; 2022 Feb; 12(1):1960. PubMed ID: 35121801
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma.
Zhang J; Ling X; Fang C; Ma J
Cell Mol Biol Lett; 2022 May; 27(1):39. PubMed ID: 35578166
[TBL] [Abstract][Full Text] [Related]
20. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
